DISC MEDICINE INC (IRON)
US2546041011 - Common Stock
DISC MEDICINE INC
NASDAQ:IRON (1/3/2025, 8:00:02 PM)
After market: 63.82 0 (0%)63.82
+1.37 (+2.19%)
Company Profile
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Company Info
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS
P: 16176749274
Employees: 74
Website: https://www.discmedicine.com/
IRON News
a month ago - Disc Medicine IncDisc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meetinga month ago - Disc Medicine IncDisc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual MeetingPositive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in...
a month ago - Disc Medicine IncDisc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meetinga month ago - Disc Medicine IncDisc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual MeetingDemonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor...
2 months ago - Disc Medicine IncDisc Medicine to Participate in Upcoming Investor Conferences2 months ago - Disc Medicine IncDisc Medicine to Participate in Upcoming Investor ConferencesWATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...
IRON Twits
Here you can normally see the latest stock twits on IRON, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
